HRP20100272T2 - Piridinaminosulfonil supstituirani benzamidi kao inhibitori citokroma p450 3a4 (cyp3a4) - Google Patents

Piridinaminosulfonil supstituirani benzamidi kao inhibitori citokroma p450 3a4 (cyp3a4) Download PDF

Info

Publication number
HRP20100272T2
HRP20100272T2 HR20100272T HRP20100272T HRP20100272T2 HR P20100272 T2 HRP20100272 T2 HR P20100272T2 HR 20100272 T HR20100272 T HR 20100272T HR P20100272 T HRP20100272 T HR P20100272T HR P20100272 T2 HRP20100272 T2 HR P20100272T2
Authority
HR
Croatia
Prior art keywords
cr12ar12b
alkyl
hydrogen
amino
sulfonyl
Prior art date
Application number
HR20100272T
Other languages
English (en)
Croatian (hr)
Inventor
Douglas Patterson Brian
Kim Sakata Sylvie
D. Nambu Mitchell
Bharat Kumar Patel Leena
Howard Tatlock John
Original Assignee
Pfizer Products Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Incorporated filed Critical Pfizer Products Incorporated
Publication of HRP20100272T1 publication Critical patent/HRP20100272T1/xx
Publication of HRP20100272T2 publication Critical patent/HRP20100272T2/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/76Nitrogen atoms to which a second hetero atom is attached
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20100272T 2005-09-23 2006-09-11 Piridinaminosulfonil supstituirani benzamidi kao inhibitori citokroma p450 3a4 (cyp3a4) HRP20100272T2 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US72015105P 2005-09-23 2005-09-23
US72311505P 2005-10-03 2005-10-03
US72546905P 2005-10-11 2005-10-11
US76225606P 2006-01-25 2006-01-25
US82166406P 2006-08-07 2006-08-07
PCT/IB2006/002639 WO2007034312A2 (en) 2005-09-23 2006-09-11 Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4)

Publications (2)

Publication Number Publication Date
HRP20100272T1 HRP20100272T1 (en) 2010-06-30
HRP20100272T2 true HRP20100272T2 (hr) 2010-07-31

Family

ID=37889174

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100272T HRP20100272T2 (hr) 2005-09-23 2006-09-11 Piridinaminosulfonil supstituirani benzamidi kao inhibitori citokroma p450 3a4 (cyp3a4)

Country Status (28)

Country Link
US (1) US7868026B2 (de)
EP (1) EP1937639B1 (de)
JP (1) JP4336738B2 (de)
KR (1) KR100975448B1 (de)
CN (1) CN101287708B (de)
AT (1) ATE459603T1 (de)
AU (1) AU2006293605B2 (de)
BR (1) BRPI0616156A2 (de)
CA (1) CA2621805C (de)
CY (1) CY1110010T1 (de)
DE (1) DE602006012713D1 (de)
DK (1) DK1937639T3 (de)
EA (1) EA014329B1 (de)
EC (1) ECSP088296A (de)
ES (1) ES2340200T3 (de)
GE (1) GEP20115230B (de)
HR (1) HRP20100272T2 (de)
IL (1) IL189666A (de)
MA (1) MA29791B1 (de)
MY (1) MY143391A (de)
NO (1) NO20081844L (de)
NZ (1) NZ566136A (de)
PL (1) PL1937639T3 (de)
PT (1) PT1937639E (de)
RS (2) RS51349B (de)
SI (1) SI1937639T1 (de)
TN (1) TNSN08139A1 (de)
WO (1) WO2007034312A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009000482A (es) * 2006-07-05 2009-01-27 Pfizer Prod Inc Compuestos terapeuticos.
WO2008088540A2 (en) * 2006-12-26 2008-07-24 Amgen Inc. N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
KR20090117950A (ko) 2007-03-08 2009-11-16 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절자 및 그것의 사용 방법
MX2010003155A (es) * 2007-10-04 2010-04-01 Hoffmann La Roche Derivados de ciclopropil aril amida y uso de los mismos.
EP2337563B1 (de) 2008-09-08 2014-04-09 The Board of Trustees of The Leland Stanford Junior University Modulatoren der aldehyddehydrogenase-aktivität und anwendungsverfahren für diese
KR20110082180A (ko) 2008-10-28 2011-07-18 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 알데히드 탈수소효소의 조절자 및 그것의 사용방법
HUE025013T2 (hu) 2009-01-12 2016-04-28 Pfizer Ltd Szulfonamid-származékok
RU2011148937A (ru) * 2009-05-01 2013-06-10 Раквалиа Фарма Инк. Производные сульфамоилбензойной кислоты в качестве антагонистов trpm8
JP5872552B2 (ja) 2010-07-09 2016-03-01 ファイザー・リミテッドPfizer Limited 化学化合物
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
WO2014000178A1 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug
CN104540813A (zh) * 2012-06-27 2015-04-22 默沙东公司 磺酰胺衍生物以及使用它们用于改善药物的药物动力学的方法
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−2調節因子およびその使用方法
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
WO2014194519A1 (en) 2013-06-07 2014-12-11 Merck Sharp & Dohme Corp. Imidazole derivatives and methods of use thereof for improving pharmacokinetics of drug
WO2015070367A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Piperidine or piperazine linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
WO2015070366A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
CN106103446B (zh) 2014-03-26 2019-07-30 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物
WO2016101118A1 (en) * 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Amidoethyl azole orexin receptor antagonists
CA2992889A1 (en) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
CN116903531B (zh) * 2023-07-21 2025-12-12 上海中医药大学 细胞色素p450酶3a4的抑制剂及其制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169763B2 (en) * 2002-02-22 2007-01-30 Oliver Yoa-Pu Hu Cytochrome P450 3A inhibitors and enhancers

Also Published As

Publication number Publication date
KR100975448B1 (ko) 2010-08-11
ECSP088296A (es) 2008-06-30
ATE459603T1 (de) 2010-03-15
PL1937639T3 (pl) 2010-07-30
NO20081844L (no) 2008-05-29
US20070167497A1 (en) 2007-07-19
SI1937639T1 (sl) 2010-07-30
RS20080118A (sr) 2009-05-06
BRPI0616156A2 (pt) 2011-06-07
EA014329B1 (ru) 2010-10-29
RS51349B (sr) 2011-02-28
PT1937639E (pt) 2010-04-23
DE602006012713D1 (de) 2010-04-15
CN101287708A (zh) 2008-10-15
JP2009508931A (ja) 2009-03-05
CA2621805C (en) 2011-05-10
NZ566136A (en) 2010-04-30
IL189666A (en) 2011-12-29
KR20080038431A (ko) 2008-05-06
AU2006293605B2 (en) 2011-05-19
WO2007034312A3 (en) 2007-08-23
DK1937639T3 (da) 2010-05-10
GEP20115230B (en) 2011-06-10
CY1110010T1 (el) 2015-01-14
CA2621805A1 (en) 2007-03-29
EA200800542A1 (ru) 2008-08-29
JP4336738B2 (ja) 2009-09-30
EP1937639A2 (de) 2008-07-02
MY143391A (en) 2011-05-13
HRP20100272T1 (en) 2010-06-30
WO2007034312A2 (en) 2007-03-29
HK1120506A1 (en) 2009-04-03
ES2340200T3 (es) 2010-05-31
CN101287708B (zh) 2012-02-29
IL189666A0 (en) 2008-08-07
AU2006293605A1 (en) 2007-03-29
US7868026B2 (en) 2011-01-11
TNSN08139A1 (fr) 2009-07-14
MA29791B1 (fr) 2008-09-01
EP1937639B1 (de) 2010-03-03

Similar Documents

Publication Publication Date Title
HRP20100272T2 (hr) Piridinaminosulfonil supstituirani benzamidi kao inhibitori citokroma p450 3a4 (cyp3a4)
AU2014223973B2 (en) Amide compounds for the treatment of HIV
AR084573A1 (es) Quinoxalinas y aza-quinoxalinas como moduladores del receptor de crth
AR126073A1 (es) N-(hidroxialquil(hetero)aril)tetrahidrofuran carboxamidas como moduladores de canales de sodio
HRP20250048T1 (hr) Inhibitori tyk2 i njihova uporaba
CA2897004C (en) (hetero) arylacetamide derivatives as antiretroviral agents
DE602004021959D1 (de) Verbindungen mit agonistischer wirkung am beta2-adrenergen rezeptor und am muscarinischen rezeptor
JP2023530319A (ja) Nav1.8阻害剤としての2-オキソ-オキサゾリジン-5-カルボキサミド
CA2672373A1 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
HRP20191821T1 (hr) Antiproliferativni spojevi i načini njihove uporabe
AR037008A1 (es) El uso del antagonista del receptor nk-1 para la elaboracion de un medicamento para el tratamiento y/o prevencion de lesiones cerebrales, espinales o neuronales y una composicion farmaceutica que comprende uno o mas de dicho antagonista.
PH12019500659A1 (en) Pyrazolopyridine derivative having glp-1 receptor agonist effect
PE20210414A1 (es) Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos
HRP20230313T1 (hr) Modulatori receptora cxcr7 piperidina
HRP20210783T1 (hr) Derivati karboksamida
HRP20250282T1 (hr) Fuzijski tri-ciklički spoj kao dvostruki inhibitor pde3/pde4
JP2016164163A (ja) Hiv複製の阻害剤
AR065824A1 (es) Sulfonilbenzamidas sustituidas con heterociclos bloqueantes de los canales de sodio,formulaciones farmaceuticas que las contienen y usos de las mismas en el tratamiento del dolor y particularmente del dolor cronico.
WO2014120815A9 (en) Quinoline and quinazoline amides as modulators of sodium channels
AR111808A1 (es) Derivados de pirimidina como moduladores del receptor de pge2
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
PE20200664A1 (es) Compuestos espirociclicos y sus metodos de preparacion y uso
RU2017145922A (ru) МОДУЛЯТОРЫ ROR ГАММА(RORy)
AR109650A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
ATE487715T1 (de) Triazolderivate als modulatoren von dopamin-d3- rezeptoren